Fly News Breaks for April 26, 2019
Apr 26, 2019 | 07:11 EDT
H.C. Wainwright analyst Raghuram Selvaraju started Oragenics with a Buy rating and $2 price target. The company has a "potentially best-in-class" treatment for oral mucositis, Selvaraju tells investors in a research note. Oragenics has a novel bacterially-based therapeutic called AG013, consisting of an oral rinse containing a genetically engineered bacterial strain that secretes trefoil family factor 1, a peptide that plays a key role in regulation of mucosal healing and restitution, says the analyst.
News For OGEN From the Last 2 Days
There are no results for your query OGEN